Retatrutide · research summary

Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.

iScience · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Comparative preclinical study evaluating anti-fibrotic and anti-inflammatory effects of GLP-1 receptor agonists in non-diabetic renal fibrosis models
“we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”

Duration

14 days of daily drug administration
“The drug was dissolved in physiological saline and administered daily for 14 days (120 μg/kg/day).”

Reported findings

In the UUO model, drug effects were associated with distinct pathways: semaglutide with PI3K-AKT inhibition, tirzepatide with PI3K-AKT inhibition and PPAR activation, and retatrutide with concurrent inhibition of PI3K-AKT and NF-κB pathways
“In the UUO model, semaglutide effects were associated with PI3K-AKT inhibition, tirzepatide effects with PI3K-AKT inhibition and PPAR pathway activation, and retatrutide effects with concurrent inhibition of both PI3K-AKT and NF-κB pathways.”
In the aging model, all three drugs were linked to mitigation of G2/M cell cycle arrest
“In the aging model, all three drugs were linked to G2/M arrest mitigation.”

Source: PubMed 42630988 · DOI 10.1016/j.isci.2026.117174 · all study summaries